

Strengths

What do you do well?
What unique resources can you draw on?
What do others see as your strengths?

Weaknesses

What could you improve?
Where do you have fewer resources than others?
What are others likely to see as weaknesses?

Opportunities

What opportunities are open to you?
What trends could you take advantage of?
How can you turn your strengths into opportunities?

Threats

What threats could harm you?
What is your competition doing?
What threats do your weaknesses expose to you?

Lung collaborative Group SWOT 6-30-2020

[illegible]

Lung collaborative Group SWOT 6-30-2020

- How do we envision the collaborations with the industry ?
- How do we improve inclusion of Minorities?
- What are the ways that we can tap into and engage with many of the other CBRG and DCP programs, i.e., CIB, MCL, Tumor Atlas, etc.
- How can we make the administration of the “set aside” process easier?
- How can we increase the capacity for accrual for future studies;
- How can we expand the role of the BRLs? Should they come in to the EDRN as a partner with the BDLs from the outset? Should the BRLs take a more active role in reaching out to BDLs with advanced development of biomarkers
- How can we add another collaborative group that is focused on common assays/technologies/biomarker validation? Would joint breakout session with 2 groups with overlapping technologies be useful?
- Can the EDRN consider the integration of small clinical trials to move clinical utility forward?
- Best means of bringing junior investigators in our collaborative group;
- How do we increase the number of collaborations between our lung collaborative group members?
- Is EDRN ready to apply Universal Cancer Approach – multianalyte for Pan Cancer Detection